Turkish Thoracic Journal
Review

What We Learned about COVID-19 So Far? Notes from Underground

1.

Department of Chest Diseases, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey

2.

Department of Chest Diseases, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey

3.

Department of Chest Diseases, Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey

4.

Department of Chest Diseases, Ufuk University, School of Medicine, Ankara, Turkey

5.

Internal Medicine Intensive Care Unit, Yüzüncü Yıl University, Dursun Odabas Medical Center, Van, Turkey

6.

Department of Pediatric Pulmonology, Gazi University School of Medicine, Ankara, Turkey

7.

Department of Pediatric Pulmonology, Hacettepe University School of Medicine, Ankara, Turkey

8.

Department of Chest Diseases, Kırıkhan State Hospital, Hatay, Turkey

9.

Department of Occupational Health and Diseases, Adana City Research and Training Hospital, Adana, Turkey

10.

Department of Chest Diseases, Kütahya University of Health Sciences, School of Medicine, Kütahya, Turkey

11.

Department of Pathology, Ankara University School of Medicine, Ankara, Turkey

12.

Department of Physiotherapy and Rehabilitation, Yeditepe University Faculty of Health Sciences, İstanbul, Turkey

13.

Department of Chest Diseases, Dokuz Eylül University School of Medicine, İzmir, Turkey

14.

Department of Chest Diseases, Yozgat City Hospital, Yozgat, Turkey

15.

Department of Chest Diseases, Çubuk Halil Sivgin State Hospital, Ankara, Turkey

16.

Department of Chest Diseases, Düzce University School of Medicine, Düzce, Turkey

17.

Internal Medicine Intensive Care Unit, Hacettepe University School of Medicine, Ankara, Turkey

18.

Department of Chest Diseases, Mersin University School of Medicine, Mersin, Turkey

19.

Department of Chest Diseases, Ardahan State Hospital, Ardahan, Turkey

20.

Department of Chest Diseases, Konak Hospital, İzmir, Turkey

21.

Department of Chest Diseases, Kestel State Hospital, Bursa, Turkey

22.

Department of Chest Diseases, Manisa Celal Bayar University School of Medicine, Manisa, Turkey

23.

Department of Chest Diseases, Denizli State Hospital, Denizli, Turkey

24.

Intensive Care Unit, Ankara Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey

25.

Department of Allergy and Immunology, Uludağ University School of Medicine, Bursa, Turkey

26.

Department of Thoracic Surgery, Ondokuz Mayıs University School of Medicine, Samsun, Turkey

27.

Department of Chest Diseases, Ordu University School of Medicine, Ordu, Turkey

28.

Department of Nursing, Yeditepe University Faculty of Health Sciences, İstanbul, Turkey

29.

Department of Chest Diseases, Baskent University School of Medicine, Ankara, Turkey

30.

Intensive Care Unit, Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, Izmir, Turkey

31.

Department of Chest Diseases, Hacettepe University School of Medicine, Ankara, Turkey

32.

Department of Chest Diseases, Ataturk University School of Medicine, Erzurum, Turkey

Turk Thorac J 2020; 21: 185-192
DOI: 10.5152/TurkThoracJ.2020.20052
Read: 35 Downloads: 42 Published: 11 June 2020

The novel coronavirus pandemic poses a major global threat to public health. Our knowledge concerning every aspect of COVID-19 is evolving rapidly, given the increasing data from all over the world. In this narrative review, the Turkish Thoracic Society Early Career Taskforce members aimed to provide a summary on recent literature regarding epidemiology, clinical findings, diagnosis, treatment, prevention, and control of COVID-19. Studies revealed that the genetic sequence of the novel coronavirus showed significant identity to SARS-CoV and MERS-CoV. Angiotensin-converting enzyme 2 receptor is an important target of the SARS-CoV-2 while entering an organism. Smokers were more likely to develop the disease and have a higher risk for ICU admission. The mean incubation period was 6.4 days, whereas asymptomatic transmission was reported up to 25 days after infection. Fever and cough were the most common symptoms, and cardiovascular diseases and hypertension were reported to be the most common comorbidities among patients. Clinical manifestations range from asymptomatic and mild disease to severe acute respiratory distress syndrome. Several patients showed typical symptoms and radiological changes with negative RT-PCR but positive IgG and IgM antibodies. Although radiological findings may vary, bilateral, peripherally distributed, ground-glass opacities were typical of COVID-19. Poor prognosis was associated with older age, higher Sequential Organ Failure Assessment score, and high D-dimer level. Chloroquine was found to be effective in reducing viral replication in vitro. Likewise, protease inhibitors, including lopinavir/ritonavir, favipiravir, and nucleoside analogue remdesivir were proposed to be the potential drug candidates in COVID-19 management. Despite these efforts, we still have much to learn regarding the transmission, treatment, and prevention of COVID-19.

Cite this article as: Tokgöz Akyıl F, Karadoğan D, Gündüz Gürkan C, et al. What We Learned about COVID-19 So Far? Notes from Underground. Turk Thorac J 2020; 21(3): 185-92.

Files
EISSN 2149-2530